STOCK TITAN
  1. Home
  2. Sec-filings
  3. CSBR
  4. [Form 4] CHAMPIONS ONCOLOGY, INC. Insider Trading Activity

CSBR Form 4: 13,790 director options at $6.80; exp. 11/05/2035

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Champions Oncology (CSBR) reported a director’s equity grant on a Form 4. The reporting person acquired an option to purchase 13,790 shares of common stock on 11/05/2025 at an exercise price of $6.80 per share. The option expires 11/05/2035 and vests over twelve months in four tranches on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026. Ownership is listed as Direct. This filing reflects routine director equity compensation and does not indicate cash proceeds to the company.

Positive

  • None.

Negative

  • None.
Insider Mendelson Daniel Newman
Role Director
Type Security Shares Price Value
Grant/Award Option to purchase Common Stock 13,790 $6.80 $94K
Holdings After Transaction: Option to purchase Common Stock — 13,790 shares (Direct)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mendelson Daniel Newman
(Last) (First) (Middle)
C/O CHAMPIONS ONCOLOGY, INC.
ONE UNIVERSITY PLAZA, SUITE 307
(Street)
HACKENSACK NJ 07601
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to purchase Common Stock $6.8 11/05/2025 A 13,790 (1) 11/05/2035 Common Stock 13,790 $6.8 13,790 D
Explanation of Responses:
1. The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.
Remarks:
/s/ Daniel Mendelson 11/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CSBR disclose in this Form 4?

A director acquired an option to purchase 13,790 shares of Champions Oncology common stock.

What is the exercise price of the reported options for CSBR?

The exercise price is $6.80 per share.

When were the options granted and when do they expire for CSBR?

Granted on 11/05/2025; the options expire 11/05/2035.

What is the vesting schedule for the CSBR director options?

They vest over twelve months on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026.

How is ownership reported for these CSBR options?

The ownership form is listed as Direct.

Who is the issuer in this Form 4 filing?

The issuer is Champions Oncology, Inc. (CSBR).